SGMO - Sangamo Therapeutics Q3 2021 Earnings Preview

Sangamo Therapeutics (NASDAQ:SGMO) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is -$0.33 and the consensus Revenue Estimate is $25.96M (-55.1% Y/Y). The company had reported second-quarter revenue that beat Wall Street estimates and reiterated its financial forecast for the year, in August. In August, Seeking Alpha contributor Marty Chilberg called Sangamo "an emerging neurogenetic therapies leader", and said that "there are numerous known and probable catalysts in the next six to twelve months". Over the last 1 year, SGMO has beaten EPS estimates 50% of the time and has beaten revenue estimates 75% of the time. Over the last 3 months, EPS estimates have seen 2 upward revisions and 5 downward. Revenue estimates have seen 1 upward revision and 2 downward. The company's shares have fallen more than 43% year to  date.

For further details see:

Sangamo Therapeutics Q3 2021 Earnings Preview